Clinical Trials Logo

Filter by:
NCT ID: NCT00131690 Completed - Birth Weight Clinical Trials

Effect of Caffeine on Fetal Growth

Start date: April 1996
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether caffeine has any effect on birth weight.

NCT ID: NCT00131261 Completed - Multiple Myeloma Clinical Trials

Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The purpose of this open-label, non-randomized trial is to assess the safety and effectiveness of PXD101, both alone and in combination with dexamethasone, in patients with advanced multiple myeloma. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Various members of this class of drugs have shown activity in preclinical studies and in initial clinical trials of multiple myeloma and lymphoma. Furthermore, HDAC inhibitors, including PXD101, have been shown to sensitize myeloma cells to the killing effect of other chemotherapeutic agents, including dexamethasone, a well-established agent in relapsing myeloma.

NCT ID: NCT00131170 Completed - Breast Cancer Clinical Trials

Paravertebral Block for Breast Surgery

Start date: September 2005
Phase: Phase 4
Study type: Interventional

The effect of paravertebral block in combination with general anaesthesia is studied in a double blind fashion.

NCT ID: NCT00129766 Completed - Clinical trials for Respiratory Syncytial Virus Infections

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among children at high risk for serious RSV disease. A secondary objective was to compare the incidence of medically-attended lower respiratory infections (LRIs) between treatment groups.

NCT ID: NCT00128882 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D

Start date: November 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to describe the effect of anti-D on symptoms and platelet count in children suffering from unexplainable low platelet counts, when anti-D is administered as an injection under the skin. The hypothesis is that the injection with anti-D under the skin is as effective as anti-D given in a vein.

NCT ID: NCT00127283 Completed - Clinical trials for Acquired Bleeding Disorder

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

FAST
Start date: May 2005
Phase: Phase 3
Study type: Interventional

This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America. The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activated)) in patients with acute intracerebral bleeding. It is expected that more patients will recover without severe permanent disability after acute treatment with Recombinant Factor VIIa by reducing further intracerebral bleeding.

NCT ID: NCT00126945 Completed - Clinical trials for Infections, Meningococcal

Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs

Start date: August 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of one dose of four different formulations of the MenACWY conjugate vaccine when given to healthy subjects aged 15-19 years. The selection of the best formulation will be based on data obtained up to one month after the vaccine dose.

NCT ID: NCT00125645 Completed - Clinical trials for Myocardial Infarction

Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)

Start date: March 1, 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare changes in global left ventricular (LV) function after 3 months of treatment with irbesartan compared with usual care in patients with acute myocardial infarction, a wall motion score >1.3 (EF>0.40) and signs of diastolic dysfunction. The hypothesis is that an angiotensin 2-receptor inhibitor will improve global left ventricular function.

NCT ID: NCT00125567 Completed - Clinical trials for Idiopathic Parkinson's Disease

Stalevo in Early Wearing-Off Patients

SEWOP
Start date: August 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian medication is required due to inadequately controlled parkinsonian symptoms.

NCT ID: NCT00125320 Completed - Atrial Fibrillation Clinical Trials

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

Start date: June 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the safety and efficacy of RSD1235 compared to placebo in the conversion of atrial arrhythmia to sinus rhythm in subjects following valvular and/or coronary artery bypass graft surgery.